Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in small cell lung cancer
NCT01635400Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2012
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan in small cell lung cancer (SCLC) (3 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Side effect of chemotherapy at 30 days. Status: unknown.
02
Drugs
irinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01635400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01635400.